[Form 4] Clene Inc. Insider Trading Activity

Rhea-AI Filing Summary

Clene Inc. (CLNN) filed a Form 4 disclosing that director Vallerie McLaughlin was granted a stock option to buy 4,092 shares of common stock. The option has an exercise price of $3.60 per share, vests immediately, and covers 4,092 underlying shares. The option grant is exercisable through an expiration date of 08/13/2035. The transaction date reported is 08/14/2025. The filing indicates the Form 4 was submitted by one reporting person and was signed under power of attorney.

Positive

• Option grant fully specified: 4,092-share option with clear exercise price of $3.60 and expiration date 08/13/2035
• Immediate vesting: the options vest immediately upon grant, giving the director full beneficial right to exercise subject to payment

Negative

• None.

Insights

Securities Analyst

TL;DR: A director received a modest option grant for 4,092 shares at $3.60, fully vested on grant.

The grant of 4,092 options to a director is a routine equity compensation event disclosed on Form 4. Key terms are explicit: exercise price $3.60, immediate vesting, underlying shares 4,092, and expiration 08/13/2035. As reported, this is a non-derivative award that increases the director's potential equity stake if exercised. The filing shows individual reporting and a power-of-attorney signature, consistent with standard insider reporting procedures.

Corporate Governance Expert

TL;DR: Immediate vesting of an option grant to a director is notable for governance disclosures but appears routine in form.

The document discloses an option grant under the companys stock plan with immediate vesting, which should be tracked for post-grant holdings and potential exercise activity. The form clearly identifies the reporting person as a director and provides all material option terms reported on Form 4. There is no additional company-level context in this filing to assess material governance shifts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McLaughlin Vallerie

(Last) (First) (Middle)

6550 SOUTH MILLROCK DRIVE

SUITE G50

(Street)

SALT LAKE CITY UT 84121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
stock option	$3.6	08/14/2025		A		4,092		(1)	08/13/2035	common stock	4,092	$0	4,092	D

Explanation of Responses:

1. This option was granted on August 14, 2025 as an option for 4,092 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The options vest immediately upon grant.

	/s/ Jerome T. Miraglia POA	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Clene Inc. (CLNN) report on this Form 4?

The Form 4 reports a stock option grant of 4,092 shares to director Vallerie McLaughlin.

What is the exercise price and number of shares for the CLNN option grant?

The option covers 4,092 shares with an exercise price of $3.60 per share.

When was the CLNN option grant executed and when does it expire?

The reported transaction date is 08/14/2025 and the option expires on 08/13/2035.

Does the CLNN option grant have any vesting conditions?

No additional vesting conditions are shown; the filing states the options vest immediately upon grant.

Who is the reporting person for this Form 4 involving CLNN?

The reporting person is Vallerie McLaughlin, identified as a director of Clene Inc.